Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Last updated: April 1, 2025
Sponsor: Boston Scientific Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Tic Disorders

Dystonia

Treatment

Radiofrequency Ablation

Clinical Study ID

NCT06553625
A4106
92802182
  • All Genders

Study Summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Study candidate is scheduled to be treated with a commercially approved BostonScientific RF system for pain or for CNS applications per local Directions for Use (DFU)

  • Signed a valid, IRB/EC/REB-approved informed consent form

Exclusion

Exclusion Criteria:

  • Meets any contraindications per locally applicable Directions for Use (DFU)

  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, thatwould limit study candidate's ability to assess pain relief or to complete studyassessments

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Radiofrequency Ablation
Phase:
Study Start date:
January 29, 2024
Estimated Completion Date:
December 31, 2035

Study Description

The objective of this study is to compile real-world outcomes of Boston Scientific Corporation commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Connect with a study center

  • Universitaetsklinikum Dusseldorf

    Dusseldorf,
    Germany

    Active - Recruiting

  • St. Georges Hospital

    London,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.